ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Staff Recommends Moving Cooperative Groups Into DCT, Increase Funding, Switch Emphasis

July 4, 1975

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Lymphoma Foundation Offers Research Grants

June 28, 1996

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

Government Shutdown Cancels NCI Site Visit To Mayo Cancer Center

October 11, 2013

New CREG Cell Kinetics Study Axed By DCTBSC

March 31, 1978